Ocular hypotensive efficacy of travoprost in patients unsuccessfully treated with latanoprost

References

• Alm A, Stjernschantz J, Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology 1995;102: 1743–52
   Google Scholar
• Alm A. Comparative phase III clinical trial of latanoprost and timolol in patients with elevated intraocular pressure. Adv Prostaglandin Thromboxane Leukot Res 1995;23:527–32
   PubMedGoogle Scholar
• Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. [Latanoprost Study Groups]. Ophthalmology 1996;103: 1916–24
   Google Scholar
• Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. [The United States Latanoprost Study Group]. Ophthalmology 1996;103:138–47
   Google Scholar
• Fristrom B. A 6-month, randomized, double-masked comparison of latanoprost with timolol in patients with open angle glaucoma or ocular hypertension. Acta Ophthalmol Scand 1996;74:140–4
   PubMedGoogle Scholar
• Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. [The Latanoprost Study Group]. Ophthalmology 1996;103:126–37
   PubMed Web of Science ®Google Scholar
• Brandt JD, Vandenburgh AM, Chen K, Whitcup SM. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial. Ophthalmology 2001;108:1023–31
   PubMed Web of Science ®Google Scholar
• DuBiner H, Cooke D, Dirks M, et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure. a 30-day comparison with latanoprost. Survey Ophthalmol 2001;45:S353–S360
   PubMed Web of Science ®Google Scholar
• Gandolfi S, Simmons ST, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001;18:110–21
   PubMed Web of Science ®Google Scholar
• Sherwood M, Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Survey Ophthalmol 2001;45:S361–S368
   PubMed Web of Science ®Google Scholar
• Higginbotham EJ, Schuman JS, Goldberg I, et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 2002;120:1286–93
   PubMed Web of Science ®Google Scholar
• Goldberg I, Cunha-Vaz J, Jakobsen JE, et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2001;10:414–22
   Google Scholar
• Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472–84
   PubMed Web of Science ®Google Scholar
• Fellman RL, Sullivan K, Ratliff M, et al. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multi-center trial. Ophthalmology 2002;109: 998–1008
   Google Scholar
• Parrish RK, Palmberg P, Sheu W-P, XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator, multicenter study. Am J Ophthalmol 2003;135: 688–703
   Google Scholar
• Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology 2003;110;609–14
   PubMed Web of Science ®Google Scholar
• Griffin BW, Williams GW, Crider JY, Sharif NA. FP prostaglandin receptors mediating inositol phosphates generation and calcium mobilization in Swiss 3T3 cells: a pharmacological study. J Pharmacol Exp Ther 1997;281:845–54
   PubMed Web of Science ®Google Scholar
• Griffin BW, Magnino PE, Pang IH, Sharif NA. Pharmacological characterization of an FP prostaglandin receptor on rat vascular smooth muscle cells (A7r5) coupled to phosphoinositide turnover and intracellular calcium mobilization. J Pharmacol Exp Ther 1998;286:411–8
   PubMed Web of Science ®Google Scholar
• Sharif NA, Xu SX, Williams GW, et al. Pharmacology of [3H]prostaglandin E1/[3H]prostaglandin E2 and [3H]prostaglandin F(2alpha) binding to EP3 and FP prostaglandin receptor binding sites in bovine corpus luteum: characterization and correlation with functional data. J Pharmacol Exp Ther 1998;286:1094–102
   PubMed Web of Science ®Google Scholar
• Hellberg MR, Sallee VL, McLaughlin MA, et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther 2001;17:421–32
   PubMed Web of Science ®Google Scholar
• Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest Ophthalmol Vis Sci 2003;44:715–21
   Google Scholar
• Sharif NA, Crider JY, Husain S, et al. Human ciliary muscle cell responses to FP-class prostaglandin analogs: phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation. J Ocul Pharmacol Ther 2003;19:437–55
   PubMed Web of Science ®Google Scholar
• Tudora C, Przydryga J, The S.T.A.R.T. Study Group. An analysis of patients switched from monotherapy latanoprost to monotherapy travoprost in the S.T.A.R.T. trial. Presented at the 2002 European Association for Vision and Eye Research Meeting [EVER]; October 2–5, 2002, Alicante, Spain
   Google Scholar
• Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol 2002;120:1268–79
   PubMed Web of Science ®Google Scholar
• The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429–40
   Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701–13
   PubMed Web of Science ®Google Scholar
• Lichter PR. Expectations from clinical trials: results of the early manifest glaucoma trial. Arch Ophthalmol 2002;120:1371–2
   PubMed Web of Science ®Google Scholar
• Zimmerman TJ, Stewart WC. Intraocular pressure, safety, and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments. J Ocul Pharmacol Ther 2003;19:405–15
   PubMed Web of Science ®Google Scholar
• Novack GD, David R, Lee P-F, et al. Effect of changing medication regimens in glaucoma patients. Ophthalmologica 1988;196:23–8
   Google Scholar
• Barnebey HS, Kwok SY. Patients’ acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther 2000;22:1204–12
   PubMed Web of Science ®Google Scholar